MENU
+Compare
EDIT
Stock ticker: NASDAQ
AS OF
Jul 3 closing price
Price
$2.57
Change
+$0.01 (+0.39%)
Capitalization
215.14M

EDIT Editas Medicine Forecast, Technical & Fundamental Analysis

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases... Show more

Industry: #Biotechnology
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EDIT with price predictions
Jul 03, 2025

EDIT's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for EDIT turned positive on July 02, 2025. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 131 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EDIT moved out of overbought territory on June 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 44 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDIT broke above its upper Bollinger Band on July 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.447) is normal, around the industry mean (16.624). P/E Ratio (0.000) is within average values for comparable stocks, (58.447). EDIT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.259). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (5.924) is also within normal values, averaging (262.371).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EDIT is expected to report earnings to fall 57.00% to -39 cents per share on July 30

Editas Medicine EDIT Stock Earnings Reports
Q2'25
Est.
$-0.40
Q1'25
Missed
by $0.36
Q4'24
Missed
by $0.22
Q3'24
Est.
$-0.75
Q2'24
Missed
by $0.12
The last earnings report on May 13 showed earnings per share of -92 cents, missing the estimate of -56 cents. With 1.91M shares outstanding, the current market capitalization sits at 215.14M.
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
265
Web
https://www.editasmedicine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KENS0.260.16
+152.94%
Kenilworth Systems Corp.
ORPB7.89N/A
N/A
Oregon Pacific Bancorp
RPHCF14.72N/A
N/A
Rohto Pharmaceutical Co.
SDRMF2.86N/A
N/A
SITEMINDER LTD
CLPBY9.36-0.12
-1.27%
Coloplast AS

EDIT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+0.39%
CRSP - EDIT
55%
Loosely correlated
+0.97%
NTLA - EDIT
49%
Loosely correlated
+0.09%
ABCL - EDIT
48%
Loosely correlated
+1.33%
PRME - EDIT
48%
Loosely correlated
+1.30%
RXRX - EDIT
47%
Loosely correlated
+1.15%
More

Groups containing EDIT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+0.39%
EDIT
(2 stocks)
61%
Loosely correlated
+0.68%